Market Access/ News/ News BioMarin gene therapy for haemophilia on course for EU approval Phil Taylor BioMarin, EU, gene therapy, haemophilia A, regulatory approval, Roctavian 0 Comment The EMA’s human medicines advisory committee has recommended that BioMarin Pharmaceutical’s haemophilia A gene therapy Roctavian be approved Share X BioMarin gene therapy for haemophilia on course for EU approval https://pharmaphorum.com/news/biomarin-gene-therapy-for-haemophilia-on-course-for-eu-approval/